PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Efficacy of a new spot-on formulation of selamectin plus sarolaner against four common tick species infesting cats in Europe.

Abstract A single application of a new spot-on formulation of selamectin plus sarolaner (Stronghold(®)Plus, Zoetis) was evaluated for efficacy against the most common tick species infesting cats in Europe. In each of the seven laboratory studies, 16 adult and purpose-bred cats were randomly allocated to one of two treatment groups based on pre-treatment tick counts. Weekly infestations with 50 unfed adult Ixodes ricinus (2 studies), Ixodes hexagonus (1 study), Dermacentor reticulatus (2 studies), or Rhipicephalus sanguineus (2 studies) were scheduled on Days -2, 5, 12, 19, 26 and 33. Cats were treated on Day 0 with the spot-on formulation at the minimum recommended label dose of 6.0mg selamectin and 1.0mg sarolaner per kg bodyweight or with a placebo. Ticks were counted 48h after treatment and after each re-infestation. No treatment-related adverse reactions were recorded in any of the studies. Geometric mean live tick counts were significantly (P≤0.0012) lower in the selamectin/sarolaner-treated group compared to the placebo-treated group at all time-points. Against I. ricinus and I. hexagonus, efficacy was ≥97.2% against existing infestations and ≥97.4% against weekly re-infestations for at least 5 weeks. Treatment was 100% effective against existing R. sanguineus infestations and was ≥95.8% for at least 4 weeks. Against D. reticulatus treatment resulted in ≥94.4% efficacy for at least 4 weeks. Thus, a single application of the new spot-on formulation of selamectin plus sarolaner at the minimum dose provides rapid treatment of existing infestations and is at least one month effective against re-infestation by all relevant European tick species in cats.
PMID
Related Publications

Efficacy of a novel oral formulation of sarolaner (Simparica™) against five common tick species infesting dogs in the United States.

Efficacy and speed of kill of a new spot-on formulation of selamectin plus sarolaner against flea infestations in cats.

Efficacy and safety of a new spot-on formulation of selamectin plus sarolaner in the treatment of naturally occurring flea and tick infestations in cats presented as veterinary patients in Europe.

Efficacy of a novel oral formulation of sarolaner (Simparica™) against four common tick species infesting dogs in Europe.

Speed of kill of a new spot-on formulation of selamectin plus sarolaner for cats against induced infestations with Ixodes ricinus.

Authors

Mayor MeshTerms
Keywords

Cat

Dermacentor reticulatus

Dose confirmation

Isoxazoline

Sarolaner

Selamectin

Tick

Topical

Journal Title veterinary parasitology
Publication Year Start




PMID- 28395754
OWN - NLM
STAT- MEDLINE
DA  - 20170411
DCOM- 20170418
LR  - 20170418
IS  - 1873-2550 (Electronic)
IS  - 0304-4017 (Linking)
VI  - 238 Suppl 1
DP  - 2017 Apr
TI  - Efficacy of a new spot-on formulation of selamectin plus sarolaner against four
      common tick species infesting cats in Europe.
PG  - S3-S7
LID - S0304-4017(17)30078-X [pii]
LID - 10.1016/j.vetpar.2017.02.028 [doi]
AB  - A single application of a new spot-on formulation of selamectin plus sarolaner
      (Stronghold(R)Plus, Zoetis) was evaluated for efficacy against the most common
      tick species infesting cats in Europe. In each of the seven laboratory studies,
      16 adult and purpose-bred cats were randomly allocated to one of two treatment
      groups based on pre-treatment tick counts. Weekly infestations with 50 unfed
      adult Ixodes ricinus (2 studies), Ixodes hexagonus (1 study), Dermacentor
      reticulatus (2 studies), or Rhipicephalus sanguineus (2 studies) were scheduled
      on Days -2, 5, 12, 19, 26 and 33. Cats were treated on Day 0 with the spot-on
      formulation at the minimum recommended label dose of 6.0mg selamectin and 1.0mg
      sarolaner per kg bodyweight or with a placebo. Ticks were counted 48h after
      treatment and after each re-infestation. No treatment-related adverse reactions
      were recorded in any of the studies. Geometric mean live tick counts were
      significantly (P</=0.0012) lower in the selamectin/sarolaner-treated group
      compared to the placebo-treated group at all time-points. Against I. ricinus and 
      I. hexagonus, efficacy was >/=97.2% against existing infestations and >/=97.4%
      against weekly re-infestations for at least 5 weeks. Treatment was 100% effective
      against existing R. sanguineus infestations and was >/=95.8% for at least 4
      weeks. Against D. reticulatus treatment resulted in >/=94.4% efficacy for at
      least 4 weeks. Thus, a single application of the new spot-on formulation of
      selamectin plus sarolaner at the minimum dose provides rapid treatment of
      existing infestations and is at least one month effective against re-infestation 
      by all relevant European tick species in cats.
CI  - Copyright (c) 2017 Zoetis Services LLC. Published by Elsevier B.V. All rights
      reserved.
FAU - Geurden, Thomas
AU  - Geurden T
AD  - Zoetis, Veterinary Medicine Research and Development, Mercuriusstraat 20, B-1930 
      Zaventem, Belgium. Electronic address: [email protected]
FAU - Becskei, Csilla
AU  - Becskei C
AD  - Zoetis, Veterinary Medicine Research and Development, Mercuriusstraat 20, B-1930 
      Zaventem, Belgium.
FAU - Vatta, Adriano F
AU  - Vatta AF
AD  - Zoetis, Veterinary Medicine Research and Development, 333 Portage Street,
      Kalamazoo, MI 49007 USA.
FAU - Slootmans, Nathalie
AU  - Slootmans N
AD  - Zoetis, Veterinary Medicine Research and Development, Mercuriusstraat 20, B-1930 
      Zaventem, Belgium.
FAU - von Reitzenstein, Marcela
AU  - von Reitzenstein M
AD  - Zoetis, Veterinary Medicine Research and Development, 333 Portage Street,
      Kalamazoo, MI 49007 USA.
FAU - King, Vickie L
AU  - King VL
AD  - Zoetis, Veterinary Medicine Research and Development, 333 Portage Street,
      Kalamazoo, MI 49007 USA.
FAU - Lin, Dan
AU  - Lin D
AD  - Zoetis, Veterinary Medicine Research and Development, Mercuriusstraat 20, B-1930 
      Zaventem, Belgium.
FAU - Rugg, Douglas
AU  - Rugg D
AD  - Zoetis, Veterinary Medicine Research and Development, 333 Portage Street,
      Kalamazoo, MI 49007 USA.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Vet Parasitol
JT  - Veterinary parasitology
JID - 7602745
RN  - 0 (Acaricides)
RN  - 0 (Isoxazoles)
RN  - 70288-86-7 (Ivermectin)
RN  - A2669OWX9N (selamectin)
SB  - IM
MH  - Acaricides/*administration & dosage
MH  - Administration, Topical
MH  - Animals
MH  - Cat Diseases/*drug therapy
MH  - Cats
MH  - Europe
MH  - Female
MH  - Isoxazoles/*administration & dosage
MH  - Ivermectin/administration & dosage/*analogs & derivatives
MH  - Male
MH  - Random Allocation
MH  - Tick Control/*standards
MH  - Tick Infestations/drug therapy/*veterinary
MH  - Ticks
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Cat
OT  - Dermacentor reticulatus
OT  - Dose confirmation
OT  - Isoxazoline
OT  - Sarolaner
OT  - Selamectin
OT  - Tick
OT  - Topical
EDAT- 2017/04/12 06:00
MHDA- 2017/04/19 06:00
CRDT- 2017/04/12 06:00
PHST- 2016/12/15 [received]
PHST- 2017/01/28 [revised]
PHST- 2017/02/23 [accepted]
AID - S0304-4017(17)30078-X [pii]
AID - 10.1016/j.vetpar.2017.02.028 [doi]
PST - ppublish
SO  - Vet Parasitol. 2017 Apr;238 Suppl 1:S3-S7. doi: 10.1016/j.vetpar.2017.02.028.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>